Safety, tolerability and pharmacokinetics of JNJ-1802, a pan-serotype dengue direct antiviral small molecule, in a Phase 1, double-blind, randomized, dose-escalation study in healthy volunteers.

Oliver AckaertFrédéric VanhoutteNathalie VerpoortenAnnemie BuelensSophie Lachau-DurandLieve LammensRichard HoetelmansMarnix Van LoockGuillermo Herrera-Taracena

Published in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023)

Pharmacokinetics and safety results of JNJ-1802 support further clinical development for the treatment and prevention of dengue infection.

Keyphrases

double blind
dengue virus
placebo controlled
open label
small molecule
zika virus
phase iii
clinical trial
aedes aegypti
phase ii
study protocol
multidrug resistant
protein protein